$CSTL
CASTLE BIOSCIENCES INC

2024 Q3 Form 10-Q Financial Statement

#000144736224000122 Filed on August 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $85.78M $87.00M
YoY Change 39.5% 73.53%
Cost Of Revenue $15.61M $14.52M
YoY Change 37.9% 31.3%
Gross Profit $70.17M $72.48M
YoY Change 39.86% 85.47%
Gross Profit Margin 81.8% 83.31%
Selling, General & Admin $50.50M $51.09M
YoY Change 13.18% 15.12%
% of Gross Profit 71.96% 70.48%
Research & Development $12.32M $14.14M
YoY Change -4.64% 6.89%
% of Gross Profit 17.56% 19.5%
Depreciation & Amortization $1.269M $1.101M
YoY Change 40.69% -63.78%
% of Gross Profit 1.81% 1.52%
Operating Expenses $62.82M $65.22M
YoY Change 9.18% 8.28%
Operating Profit $5.079M $5.012M
YoY Change -152.69% -123.69%
Interest Expense $192.0K $216.0K
YoY Change 9500.0% -90.98%
% of Operating Profit 3.78% 4.31%
Other Income/Expense, Net
YoY Change
Pretax Income $8.282M $7.886M
YoY Change -220.55% -142.03%
Income Tax $6.013M -$1.034M
% Of Pretax Income 72.6% -13.11%
Net Earnings $2.269M $8.920M
YoY Change -132.86% -147.5%
Net Earnings / Revenue 2.65% 10.25%
Basic Earnings Per Share $0.08 $0.32
Diluted Earnings Per Share $0.08 $0.31
COMMON SHARES
Basic Shares Outstanding 27.74M shares 27.61M shares
Diluted Shares Outstanding 29.40M shares 28.74M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $279.8M $259.7M
YoY Change 21.81% 15.16%
Cash & Equivalents $95.00M $85.60M
Short-Term Investments $184.8M $174.1M
Other Short-Term Assets $8.154M $6.716M
YoY Change 14.85% 9.9%
Inventory $6.572M $8.013M
Prepaid Expenses
Receivables $50.26M $45.99M
Other Receivables $0.00 $0.00
Total Short-Term Assets $344.8M $320.4M
YoY Change 23.3% 19.09%
LONG-TERM ASSETS
Property, Plant & Equipment $56.29M $50.26M
YoY Change 152.71% 56.81%
Goodwill $10.70M $10.70M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.831M $2.683M
YoY Change 16.92% 125.46%
Total Long-Term Assets $169.8M $166.9M
YoY Change 8.57% 6.75%
TOTAL ASSETS
Total Short-Term Assets $344.8M $320.4M
Total Long-Term Assets $169.8M $166.9M
Total Assets $514.6M $487.3M
YoY Change 18.01% 14.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.810M $9.540M
YoY Change -1.72% 33.71%
Accrued Expenses $34.46M $26.97M
YoY Change 30.54% 17.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $44.30M $39.45M
YoY Change 21.94% 17.02%
LONG-TERM LIABILITIES
Long-Term Debt $10.02M $10.01M
YoY Change 21193.62%
Other Long-Term Liabilities $14.69M $13.65M
YoY Change 40708.33% 9.8%
Total Long-Term Liabilities $10.02M $10.01M
YoY Change 27719.44% -19.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.30M $39.45M
Total Long-Term Liabilities $10.02M $10.01M
Total Liabilities $73.51M $63.42M
YoY Change 46.33% 36.0%
SHAREHOLDERS EQUITY
Retained Earnings -$209.7M -$212.0M
YoY Change -2.83% 1.48%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $441.1M $423.9M
YoY Change
Total Liabilities & Shareholders Equity $514.6M $487.3M
YoY Change 18.01% 14.55%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $2.269M $8.920M
YoY Change -132.86% -147.5%
Depreciation, Depletion And Amortization $1.269M $1.101M
YoY Change 40.69% -63.78%
Cash From Operating Activities $23.34M $24.00M
YoY Change 364.9% -733.86%
INVESTING ACTIVITIES
Capital Expenditures $6.378M $5.229M
YoY Change 159.27% 29.59%
Acquisitions
YoY Change
Other Investing Activities -$8.411M -$16.19M
YoY Change 16.01% 42.6%
Cash From Investing Activities -$14.79M -$21.42M
YoY Change 52.31% 39.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 838.0K 42.00K
YoY Change 1576.0% -81.42%
NET CHANGE
Cash From Operating Activities 23.34M 24.00M
Cash From Investing Activities -14.79M -21.42M
Cash From Financing Activities 838.0K 42.00K
Net Change In Cash 9.387M 2.623M
YoY Change -302.31% -113.84%
FREE CASH FLOW
Cash From Operating Activities $23.34M $24.00M
Capital Expenditures $6.378M $5.229M
Free Cash Flow $16.96M $18.77M
YoY Change 562.5% -339.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27711024 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27711024 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
385149000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
12849000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
89000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-534000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29204000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47981000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5932000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
26374000 usd
CY2024Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
363000 usd
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
959000 usd
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-1705000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87002000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50138000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
159976000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
92175000 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12849000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
245000 usd
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27410532 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27410532 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18777000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
399150000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
13525000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-314000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1652000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18777000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
378768000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
391269000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
12675000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-474000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1708000 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-247000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2534000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
402462000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
13179000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-615000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-61000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
8920000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
423893000 usd
us-gaap Net Income Loss
NetIncomeLoss
6386000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6688000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
25854000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1542000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
13000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3422000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2282000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-83000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-213000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7620000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7978000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
294000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-158000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
71000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2141000 usd
cstl Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-678000 usd
cstl Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
469000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-143000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
80000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1650000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3071000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-432000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
958000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7706000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7060000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
68000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2047000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
17163000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29225000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14381000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7373000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
113194000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
86438000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
86450000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
95000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41118000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1197000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
73000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
184000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1089000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
848000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1749000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1688000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
47000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
70000 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
10000000 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10686000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
954000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13269000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27074000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98841000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122948000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85572000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95874000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
8920000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2148000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
728000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
485000 usd
cstl Decrease In Operating Lease Assets With Corresponding Change In Lease Liabilities
DecreaseInOperatingLeaseAssetsWithCorrespondingChangeInLeaseLiabilities
-7000 usd
cstl Decrease In Operating Lease Assets With Corresponding Change In Lease Liabilities
DecreaseInOperatingLeaseAssetsWithCorrespondingChangeInLeaseLiabilities
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
166000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
cstl Property And Equipment Acquired With Tenant Improvement Allowance
PropertyAndEquipmentAcquiredWithTenantImprovementAllowance
0 usd
cstl Property And Equipment Acquired With Tenant Improvement Allowance
PropertyAndEquipmentAcquiredWithTenantImprovementAllowance
1236000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212000000.0 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85600000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
174100000 usd
us-gaap Use Of Estimates
UseOfEstimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realizability of deferred tax assets, the useful lives and recoverability of long-lived assets, the goodwill impairment test, the valuation of acquired intangible assets and the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the financial institutions in which deposits are held.
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
12573000 usd
CY2023Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
21706000 usd
cstl Contract With Customer Payment Terms
ContractWithCustomerPaymentTerms
P30D
CY2023Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-88000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18777000 usd
us-gaap Net Income Loss
NetIncomeLoss
6386000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47981000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27646000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26733000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27566000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26670000 shares
CY2024Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Stock Options
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsStockOptions
440000 shares
CY2023Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Stock Options
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsStockOptions
0 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Stock Options
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsStockOptions
441000 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Stock Options
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsStockOptions
0 shares
CY2024Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Restricted Stock Units Rs Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsRestrictedStockUnitsRSUs
546000 shares
CY2023Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Restricted Stock Units Rs Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsRestrictedStockUnitsRSUs
0 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Restricted Stock Units Rs Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsRestrictedStockUnitsRSUs
427000 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Restricted Stock Units Rs Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsRestrictedStockUnitsRSUs
0 shares
CY2024Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Performance Stock Units Ps Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsPerformanceStockUnitsPSUs
98000 shares
CY2023Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Performance Stock Units Ps Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsPerformanceStockUnitsPSUs
0 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Performance Stock Units Ps Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsPerformanceStockUnitsPSUs
98000 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Performance Stock Units Ps Us
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsPerformanceStockUnitsPSUs
0 shares
CY2024Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsESPP
8000 shares
CY2023Q2 cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsESPP
0 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsESPP
10000 shares
cstl Incremental Common Shares Attributable To Dilutive Effect Of Share Based Payment Arrangements Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfShareBasedPaymentArrangementsESPP
0 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28738000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26733000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28542000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26670000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3595000 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7197000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3603000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7240000 shares
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
174288000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
177000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
174116000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
144122000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
143000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
144258000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
cstl Debt Securities Available For Sale Impairment Loss
DebtSecuritiesAvailableForSaleImpairmentLoss
0 usd
cstl Debt Securities Available For Sale Impairment Loss
DebtSecuritiesAvailableForSaleImpairmentLoss
0 usd
CY2023Q2 cstl Debt Securities Available For Sale Impairment Loss
DebtSecuritiesAvailableForSaleImpairmentLoss
0 usd
CY2024Q2 cstl Debt Securities Available For Sale Impairment Loss
DebtSecuritiesAvailableForSaleImpairmentLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
48908000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
33544000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
10270000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
8111000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
38638000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
25433000 usd
CY2024Q1 cstl Property Plant And Equipment Acquisition Of Land
PropertyPlantAndEquipmentAcquisitionOfLand
23 acre
CY2024Q2 us-gaap Depreciation
Depreciation
1101000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
792000 usd
us-gaap Depreciation
Depreciation
2194000 usd
us-gaap Depreciation
Depreciation
1462000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
10700000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
10700000 usd
CY2023Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2024Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
125880000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
23731000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
102149000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
125880000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19237000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
106643000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2200000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4500000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2200000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4500000 usd
CY2024Q2 cstl Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
2947000 usd
CY2023Q4 cstl Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
3475000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2610000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2097000 usd
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
937000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
896000 usd
CY2024Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
955000 usd
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
849000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7449000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7317000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
0 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10200000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
192000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
10008000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10008000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10200000 usd
CY2024Q2 cstl Long Term Debt Principal Maturity Remainder Of Fiscal Year
LongTermDebtPrincipalMaturityRemainderOfFiscalYear
0 usd
CY2024Q2 cstl Long Term Debt Principal Maturity Year One
LongTermDebtPrincipalMaturityYearOne
278000 usd
CY2024Q2 cstl Long Term Debt Principal Maturity Year Two
LongTermDebtPrincipalMaturityYearTwo
3333000 usd
CY2024Q2 cstl Long Term Debt Principal Maturity Year Three
LongTermDebtPrincipalMaturityYearThree
3333000 usd
CY2024Q2 cstl Long Term Debt Principal Maturity Year Four
LongTermDebtPrincipalMaturityYearFour
3056000 usd
CY2024Q2 cstl Long Term Debt Principal
LongTermDebtPrincipal
10000000 usd
CY2024Q2 us-gaap Interest Costs Incurred
InterestCostsIncurred
228000 usd
us-gaap Interest Costs Incurred
InterestCostsIncurred
241000 usd
CY2024Q2 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
12000 usd
us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
12000 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
216000 usd
us-gaap Interest Expense
InterestExpense
229000 usd
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
0 usd
CY2023Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3208979 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20845 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
25758 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
41.19
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3162376 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9011000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2798447 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8987000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
400000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
400000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
600000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
1100000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13179000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25854000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25854000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26374000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26374000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
94633000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.131
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.183
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001447362-24-000122-index-headers.html Edgar Link pending
0001447362-24-000122-index.html Edgar Link pending
0001447362-24-000122.txt Edgar Link pending
0001447362-24-000122-xbrl.zip Edgar Link pending
cstl-20240630.htm Edgar Link pending
cstl-20240630.xsd Edgar Link pending
cstl-20240630_cal.xml Edgar Link unprocessable
cstl-20240630_def.xml Edgar Link unprocessable
exhibit101-nonxemployeedir.htm Edgar Link pending
exhibit311-q22024.htm Edgar Link pending
exhibit312-q22024.htm Edgar Link pending
exhibit321-q22024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
cstl-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cstl-20240630_htm.xml Edgar Link completed
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cstl-20240630_lab.xml Edgar Link unprocessable